Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Lupus Survival Is Improving Slowly

Will Boggs, MD  |  October 30, 2017

NEW YORK (Reuters Health)—Systemic lupus erythematosus (SLE) mortality has declined during the past 46 years in the U.S.—but more slowly than mortality in the general population, according to a nationwide study.

“Based on our experience in the clinic and according to previous reports showing improvement in the short-term (five- to 10-year) survival in lupus, I was expecting to see a greater decrease in lupus mortality rate over time,” Dr. Ram R. Singh from University of California, Los Angeles, tells Reuters Health by email. “So, I was surprised to find that lupus mortality rate has decreased only 24% in a 46-year period, whereas mortality from all other causes has decreased 44% in the same 46-year period.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“I was most disturbed by the finding that (the) lupus death rate relative to (the) death rate due to all other causes (the ratio) is actually 35% higher in 2013 than in 1968,” he says.

As a result of diagnostic and therapeutic developments, five- and 10-year survival rates for SLE patients improved from less than 50% in the 1950s to more than 90% in the 1980s.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

To explore what has changed since then, Dr. Singh and colleagues examined age-standardized mortality rates (ASMRs) for individuals with or without SLE from 1968 through 2013, focusing on trends by sex, race/ethnicity, and geographic region.

The findings were published online Oct. 30 in Annals of Internal Medicine.1

The ASMR for SLE decreased from 0.45 per 100,000 persons in 1968 to 0.34 per 100,000 persons in 2013, a relative decrease of 24.4%.

During the same period, the non-SLE ASMR declined by 43.9%.

The ratio between SLE and non-SLE mortality increased between 1975 and 1998, but showed a sustained decrease after 1998. However, in 2013, the ratio remained 34.6% higher than in 1968.

SLE mortality stratified by race/ethnicity was higher in women than men in all racial/ethnic groups, whereas the adjusted odds ratio (SLE to non-SLE) and mortality differences were largest in non-Hispanic black people and smallest in non-Hispanic white people.

For all racial/ethnic groups, SLE mortality risk was greater in all other geographic regions relative to the Northeast, except for non-Hispanic black persons in the Midwest and Hispanic persons in the South and Midwest.

SLE mortality risk was more than three times higher among patients age 65 or older than among younger patients.

“Non-white persons and older individuals with lupus have a relatively higher risk of death from lupus and may need additional attention,” Dr. Singh says.

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:mortalitymortality ratesSLEsystemic lupus erythematosus (SLE)

Related Articles

    A 46-Year Study Traces the Lupus Death Rate from 1968–2013

    September 20, 2018

    A study published in Annals of Internal Medicine in December 2017 looked at trends in lupus mortality over a 46-year period. The researchers say they set out to close some knowledge gaps. “There [was] a knowledge gap relating to the large differences we see in death rates from one study to another, which could have…

    Studies Highlight Risk of Damage from Lupus Treatments

    April 20, 2017

    WASHINGTON, D.C.—Conference goers who braved the final day of the 2016 ACR/ARHP Annual Meeting were awarded for their stamina by learning about issues relating to the damage caused by systemic lupus erythematosus (SLE) during the session Systemic Lupus Erythematosus—Clinical Aspects and Treatment V: Damage and Morbidity. Minimizing Damage: Early Use of GC-Sparing Strategies Jayne Little,…

    A Better Family Plan

    October 1, 2007

    How to minimize the risks of pregnancy for women with SLE

    T Cells in Systemic Lupus Erythematosus

    August 1, 2011

    Progress toward targeted therapy

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences